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Abstract 
 
Understanding the relationship of Single Nucleotide Polymorphisms (SNPs) with the 
incidence of disease is a step towards individualized medicine. The main objective of this 
study is to explore the potential association of SNPs in Vitamin K epoxide reductase complex 
subunit 1 (VKORC1) gene and Growth Arrest- Specific 6 (GAS6) gene with the occurrence of 
unexplained Recurrent Pregnancy Loss (RPL) and Breast Cancer. 
 
Variants in VKORC1 gene have been found to affect the amount of reduced vitamin K 
(VK), a cofactor for γ-carboxylation of vitamin K–dependent proteins. The C allele of the 
VKORC1 +2255 T/C SNP is associated with higher activity at this locus and has been linked to 
increased vascular events. VK is important for post-modification of clotting factors involved 
in the coagulation cascade and Vitamin K2 (VK2) exerts an apoptotic effect on cancer cells. 
Studying a polymorphism which affects the status of VK in the body may be significant for a 
thrombophilia approach to unexplained RPL and Breast Cancer incidence.   
 
Gas6 (Growth Arrest- Specific 6) is a Vitamin K dependent protein that exerts an 
anti-apoptotic effect by interacting with receptor tyrosine kinase, TAM family; Tyro3, Axl and 
MerTK. GAS6 expression has been found to be up-regulated in several types of cancer; this 
protein is also involved in clot stability. The A allele of the GAS6 polymorphism c.834+7G>A 
may have a protective role against thrombophilia. This allele is possibly linked with a 
decrease in expression. The GAS6 c.834+7G>A SNP was explored for a potential protective 
role in cancer and RPL.  
 
The same SNPs were screened in both Breast Cancer and RPL cases, but were 
considered for different prospects and each was approached as a separate case- control 
type study. Genotyping was preformed by using NcoI and AlwN I restriction enzymes for 
VKORC1 and GAS6 SNPs, respectively.  
 
 
iv 
 
In the RPL study, 45 patients and 77 age matched controls were screened at the loci 
in question, no significant difference in haplotype distribution was observed for either GAS6 
c.834+7G>A (P = 0.83) or VKORC1 +2255 T/C (P = 0.20) among the groups. This 
polymorphism maybe thrombophilia unrelated in the unexplained RPL cases.  Further 
research is recommended to explore the significance of these SNPs in the Palestinian 
population.  
 
In the Breast Cancer study, 81 patients and 84 controls were analysed for the 
indicative haplotypes. No significant difference was observed in the allele distribution for the 
GAS6 c.834+7G>A SNP among all participants (P = 0.32). However, a significant difference in 
haplotype distribution for the VKORC1 +2255T/C SNP was observed (P = 0.02). The TT 
haplotype was found in 32% of the Breast Cancer patients, and in only 16.7% of the control 
group. The CC and CT haplotypes were found in 83.3% of controls and 67.9% of patients. The 
T allele conferred a more than 2 fold increased risk for developing Breast Cancer OR 2.36, 
95% CI (1.13 - 4.95).  
Further work is needed to explain the association of the T allele of the VKORC1 gene with 
Breast Cancer and other factors which may affect VK status in the body.  
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Chapter I 
Introduction 
 
 
Single nucleotide polymorphisms (SNPs) are the most common genetic 
variations among humans; it is a change in a single nucleotide at any location in the 
genome. Studying the pattern among SNPs in specific targeted genes and the 
incidence of a particular disease or response to a medical treatment, is one of the first 
steps towards a more individualized and prophylactic approach to medicine. Case-
control SNP association studies are increasingly popular, populations may differ 
drastically in haplotype frequencies, therefore the findings of one study does not 
necessarily apply to all. It is important for research in this area to be conducted in the 
Palestinian population, in order to help transform our current health system to a more 
personalized approach. This thesis will explore the potential association between 
SNPs in the VKORC1 and GAS6 genes with the occurrences of Breast Cancer and 
Recurrent Pregnancy Loss (RPL). The background information for the rationale of 
this study is provided in the sections of this chapter.   
 
  
1.1.1 Vitamin K  
 
Vitamin K is a fat-soluble vitamin discovered in the 1930s, during cholesterol 
experiments in chickens (Dam and Schonheyder, 1934). Vitamin K (VK) is a collective term 
for several related chemical compounds, they all share a 2-methyl-1, 4 naphthoquinone 
backbone structure, but differ in the composition of the side chain at position C-3 
(Oldenburg et al., 2008). Vitamin K1 (VK1), also known as phylloquinone, is present in 
cyanobacteria and plants; it possesses a mostly saturated C-20 phytyl side chain. Vitamin K2 
(VK2) is produced by microbial organisms and is characterized by a partly unsaturated, 
predominantly C-40 side chain (menaquinone). In organisms that produce VK, both types are 
involved in electron transport processes (Oldenburg et al., 2008). 
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Fig 1.1 Vitamin K structures (Wallin R et al., 2008) 
 
1.1.2 Vitamin K dependent proteins 
Vitamin K is an essential participant in posttranscriptional modification of proteins 
involved in coagulation, calcium metabolism, and other physiological processes (Oldenburg 
et al., 2008). All of these proteins are modified by carboxylation of glutamic acid residues to 
form γ-carboxyglutamic acid (Gla), in the absence of vitamin K the carboxylation does not 
occur and the proteins are biologically inactive (Oldenburg et al., 2008). VK dependent 
proteins in the coagulation cascade include the clotting factors II, VII, IX, X, and 
anticoagulant proteins C, S and Z which are integral to regulating hemostasis (Martinez and 
Barsigian, 1998). Each of these proteins is γ-carboxylated at several amino terminal glutamyl 
residues, which enables Ca
+2
 binding (Garcia and Reitsma, 2008 and Oldenburg et al., 2008). 
 
 Osteocalcin and matrix Gla-protein are γ-carboxylated proteins involved in bone 
metabolism. Gas6 is another VK dependent protein; some of its functions include cell growth 
and survival.  In addition, four presumed carboxylated transmembrane proteins (abbreviated 
as PRGP1, PRGP2, TmG3, and TmG4) are predicted to be VK dependent although their 
biological function remains to be identified (Kulman et al., 2001 and Oldenburg et al., 2006). 
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1.1.3 The Vitamin K cycle 
 
Vitamin K-dependent γ-carboxylation is carried out through a multi-component 
system of proteins located in the endoplasmic reticulum membrane (Furie and Furie, 1992). 
This system is composed of γ-carboxylase and vitamin K 2,3-epoxide reductase (VKOR). 
During γ-carboxylation, the hydroquinone cofactor is converted to the metabolite vitamin K 
2,3-epoxide, which is subsequently returned to the reduced form by VKOR. This 
interconversion of vitamin K metabolites is referred to as the vitamin K cycle (Wallin et al., 
2008). Fig 1.2 summarizes γ-carboxylation and the VK cycle. 
 
Fig 1.2 Vitamin K-dependent γ-carboxylation and VK cycle  
(Vit. K1H2 ) reduced form of VK, (Vit. K1 > O) VK 2,3-epoxide , and (vitamin K 2,3-epoxide reductase) 
(Wallin et al., 2008) 
 
1.1.4 Vitamin K epoxide reductase complex subunit 1 (VKORC1) Gene 
 
VKOR enzyme is a three- transmembrane structure in the rough endoplasmic 
reticulum, this protein has 163 amino acids and is coded for by the VKORC1 gene (Oldenburg 
et al., 2008 and Rost et al., 2004).  The VKORC1 gene spans 5126 base pairs on human 
chromosome 16 and contains three exons (Rost et al., 2004). VKORC1 belongs to a large 
family of homologous genes found in vertebrates, insects, plants, protists, archea, and 
bacteria. All orthologs contain the same five completely conserved amino acids, including 
two cysteines found in a tetrapeptide motif that is apparently required for redox function 
(Garcia and Reitsma, 2008). 
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1.1.5 VKORC1 Polymorphisms 
 
The anticoagulant warfarin targets the enzyme VKOR (Wallin et al., 2008); a strong 
link between SNPs in the VKORC1 gene and the requirement of warfarin dosage has been 
established. SNPs in VKORC1 could reduce VKOR activity, like R98W, or result in warfarin 
resistance, like R58G, V29L, V45A, and L128R (Garcia and Reitsma, 2008). 
 
Ten common non-coding SNPs in the VKORC1 gene were identified, seven of which 
were significantly associated with warfarin dose maintenance. Five of these seven SNPs 
were strongly correlated with one another and can reflect the natural haplotype block of 
VKORC1 (Siguret et al., 2008). These 5 common non-coding polymorphisms are; “–1639A/G 
(rs9923231) in the promoter region, +1173T/C (rs9934438) in the first intron, +1542C/G 
(rs8050894)
 
and +2255T/C (rs2359612) in the second intron, and +3730G/A
 
(rs7294) in the 3' 
downstream region”
 
(Wang et al., 2006). These SNPs are located at positions 3673, 6484, 
6853, 7566 and 9041 in the GenBank reference sequence (Wang et al., 2006). VKORC1 
mRNA levels varied according to the haplotype combination, mRNA levels in the group with 
the G-C-G-C-A
 
(3673-6484-6853-7566-9041) haplotype were 3 times as high as
 
those in the 
wild-type group and the promoter with the G allele yielded a 44% increase of
 
activity 
compared with the A allele of –1639 (Yuan et al., 2005 and Rieder et al., 2005). 
 
 The C allele of SNP +2255T/C conferred almost twice the probability of vascular 
disease in a Chinese study and the T allele of SNP +1173T/C was found to be lower among 
healthy individuals in comparison to their venous thromboembolism counterparts in a 
French study (Wang et al., 2006 and Lacut et al., 2007).  The prevalence of VKORC1 
haplotypes differ among ethnic groups (Rieder et al., 2005). 
 
1.1.6 Vitamin K2 and Apoptosis  
 
VK2 has been shown to suppress cancer growth; it induces apoptosis and 
differentiation in various cancer cells such as, leukaemia cells and hepatocellular carcinoma 
cells (Mizuta et al., 2008). VK2 is clinically used to suppress the onset of leukemia from 
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myelodysplastic syndrome (Mizuta et al., 2008).  The side chain of VK2 appears to play an 
important role in its functions (Sakai et al., 1994). 
VK2 has been shown to induce cell cycle arrest at G1/S, leading to growth inhibition of 
hepatoma cells both in vivo and in vitro. The expression levels of several growth-related 
genes, such as cyclin D1 and cyclin-dependent kinase 4 (Cdk4), and cyclin dependent kinase 
inhibitors, including p21 and/or p27, are altered in the growth-inhibitory process induced by 
VK2 (Mizuta et al., 2008). 
Ovarian cancer TYK-nu cells treated with VK2; undergo apoptosis by reduction in 
mitochondria membrane potential, activation of caspase 3, and release of cytochrome c into 
the cytosol, and DNA fragmentation (Shibayama-Imazu et al., 2008). VK2 induces apoptosis 
through one or more mitochondrial pathways (Green and Reed, 1998). 
 
1.2 Growth Arrest Specific 6 (GAS6)  
 
The GAS6 gene spans 43.8Kb on chromosome 13 and constitutes 15 exons (Muñoz 
et al., 2004). Expression of the GAS6 was found to be upregulated 30 times when a cell 
enters the G0 phase of the cell cycle ( Bellido-Martı´n and de Frutos, 2008). Gas6 is a VK 
dependent multimodular protein; it requires several post-transcriptional γ-carboxyglutamic 
acid modifications (Hansson et al., 2005). Gas6 serves as a ligand for the TAM family of 
receptor tyrosine kinases, (Tyro3, Axl and MerTK) and incomplete carboxylation of this 
protein results in loss of biological activity (Merli and Fink. 2008). Gas6 exhibits a broad 
range of regulatory functions associated with cell growth regulation, migration and 
proliferation, cell survival, apoptosis, recognition of dying cells, phagocytosis, and cell 
adhesion (Merli and Fink. 2008). 
 
1.2.1 GAS6 and Hemostasis  
 
Studies focusing on the role of Gas6 in coagulation pathways have shown that Gas6 
is a platelet response amplifier that plays a significant role in pathological thrombosis. 
Inhibition of Gas6 or the Axl receptor has been achieved in mouse models (Angelillo-
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Scherrer et al., 2005). “When the receptor is blocked initial platelet aggregation does occur, 
but stabilisation of platelet aggregates is impaired and mice are protected against life-
threatening thrombosis (Mc Cormack, 2008)”. 
 
The SNP c.834+7 G >A, located on intron 8 of the GAS6 gene was found to be 
protective against stroke (Muñoz, 2004). The AA haplotype was less prevalent among 
patients with stroke and acute coronary syndrome compared to their healthy counterparts 
(Muñoz, 2007 and Jiang, 2009). The effect of the different haplotypes on the function of this 
gene has not been elucidated. Therefore it is not clear if the genetic association with 
cardiovascular disease is related to GAS6 or reflects a linkage to other genes in the same 
chromosomal region (Muñoz, 2007).    
 
1.2.2 Anti-apoptotic effect of Gas6 
 
Gas6 was identified as a growth factor and a rescue factor from apoptosis among 
different cell types, specifically in cultured cells deprived of serum (Bellido-Martı´n and de 
Frutos, 2008). The anti-apoptotic effect of Gas6 has been found in numerous experimental 
settings and among different species. Some of the cell types and lines tested include; NIH3T3 
fibroblasts, vascular smooth muscle cells, endothelial cells, chondrocytes, neurons, 
oligodendrocytes, hepatocytic precursors, epithelial cells and different types of cancer cells 
(Bellido-Martı´n and de Frutos, 2008).The anti-apoptotic effect of Gas6 requires protein 
phosphorylation and in most cases the PI3K pathway has been demonstrated to be crucial 
for this effect (Bellosta et al., 1997). 
 
In certain tumor types, migration and invasiveness has been correlated with the 
expression of Gas6 receptors, in particular Axl and Gas6-dependent signaling through Axl has 
been shown to promote invasiveness of glioma cells in animal models (Bellido-Martı´n and 
de Frutos, 2008). 
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In breast cancer cell lines, GAS6 is upregulated more than 23-fold by progesterone 
acting through the progesterone receptor B and membrane staining of the receptor for 
Gas6, Axl, has been reported to be higher in cancerous tissue than in the normal breast 
(Richer et al., 2002 and Berclaz et al., 2001). Furthermore, the GAS6 locus has recently been 
described as a target for amplification in mouse models of breast cancer and in human 
breast cancer (Abba et al., 2007). 
 
1.3 Recurrent Pregnancy Loss 
 
Miscarriage or spontaneous abortion occurs when a pregnancy ends naturally 
before a fetus is developed enough to survive outside of the uterus. Approximately 20% of 
all pregnancies end in miscarriage (American Medical Association, 2004).  Spontaneous 
abortion is one of the most common obstetrical complications, if a women has a history of 
three or more consecutive miscarriages prior to 20 weeks of gestation, it is defined as 
Recurrent Pregnancy Loss (RPL) ( Pabinger, 2005). RPL affects approximately 0.5 – 3 % of 
women, (Li et al., 2002) usually causing emotional distress and depression. 
  RPL is a very heterogeneous disease and the etiology for half of the cases remains 
unexplained ( Kwak-Kim, 2009).  The nature of this disease presents a great challenge to 
physicians. It requires each patient to have an individual treatment plan based on their 
special needs.  Some of the identifiable causes for RPL include; Parental chromosomal 
anomalies , Uterine abnormalities, Endocrinological disorders, Immuniological factors,  
Cervical weakness, Infections, maternal diseases and Thrombophilia ( Li et al., 2002). 
 
1.3.1 Thrombophilia 
  
Thrombophilia is a term used to describe Hypercoagulability disorders that cause a 
predisposition to thrombosis (Martens and Emed, 2007). It is a multi- factorial defect, which 
can be inherited, acquired or influenced by environmental and life style factors (Walker, 
2000). Some of the clinical manifestations of Thrombophilia include; Deep Vein Thrombosis 
(DVT), Pulmonary Embolism, Purpura fulminans, stroke, and acute myocardial infarction. 
Thrombophilia is also linked to several pregnancy complications such as, recurrent 
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pregnancy loss, intrauterine growth restriction, stillbirth, severe pre-eclampsia, and abruptio 
placentae ( Heit, 2007). 
The major heritable forms of thrombophilia consist of deficiencies in anti-coagulants; 
protein C, protein S and antithrombin. Furthermore, abnormalities in pro-coagulant factors 
have been correlated with thrombophilia, particularly, factor V Leiden and the prothrombin 
G20210A gene polymorphisms. In addition, homozygosity for methylenetetrahydrofolate 
reductase (MTHFR) C677T can be associated with hyperhomocysteinaemia, which is 
correlated with increased risk of vascular events (Robertson et al., 2006). 
Supportive data in the literature also suggests a role for increased concentration of 
plasma factors I (fibrinogen), II (prothrombin), VIII, IX, XI and polymorphisms in Factor XIII 
with thrombophilia ( Heit, 2007). Dysfibrinogenemia and Reduced tissue factor pathway 
inhibitor also increases tendency for thrombosis ( Heit, 2007).  
 
Acquired thrombophilia is a result of; surgery and trauma, prolonged 
immobilization, older age, cancer, pregnancy and the puerperium, use of contraceptives or 
hormone-replacement therapy and antiphospholipid antibodies          (Seligsohn and 
Lubetsky, 2001).  
 
1.3.2 Thrombophilia and Recurrent pregnancy loss  
 
Normal pregnancy is accompanied by changes in coagulation that have likely 
evolved to protect women from the bleeding challenges of miscarriage and childbirth. 
Consequently, pregnant women are at an increased risk of thrombosis (James et. al, 2005).  
The possibility of thromboembolism increases 4- to 5-folds during pregnancy and the 
postpartum period; eighty percent of these events occur in veins with an incidence of 
approximately 2 per 1000 pregnancies (James, 2009
A
). 
 
Usually pregnancy is associated with an increase in the concentrations of factors VII, 
VIII, X, von Willebrand factor and fibrinogen whereas; Factors II, V and IX are relatively 
unchanged (Bremme, 2003).  In addition, Plasminogen activator inhibitor type 1 (PAI-1) 
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levels are increased fivefold and the levels of PAI-2, produced by the placenta, increase 
dramatically during the third trimester (James, 2009 B). PAI type 1 and 2 inhibit the activity of 
tissue Plasminogen activator (tPA) and Urokinase which consequently decreases the 
conversion of Plasminogen to Plasmin and inhibits fibrinolysis (Cesarman-Maus, 2005).  As 
gestation progresses, there is also a significant fall in the activity of activated protein C and a 
decrease in protein S, both are important anticoagulants (Bremme, 2003). These changes, 
which may not completely return to baseline until more than 8 weeks after birth, begin with 
conception and result in the hypercoagulable state of pregnancy (James, 2009 
B
) . 
Numerous case–control studies have investigated the impact of thrombophilia on 
pregnancy loss. In most of these studies factor V Leiden (FV 1691 G/A), prothrombin 20210 
A/G and the methylene tetrahydrofolate reductase (MTHFR) gene 677 C/T variations were 
considered (Pabinger, 2005).  The association of these genetic variants with RPL showed 
conflicting results in different populations.  
 
Several studies have been conducted on Palestinian women suffering from RPL; in 
one report, a significant correlation was established between the occurrences of the Factor 
V Leiden mutation and poor pregnancy out come (Hussein, 2010). 
In another study carried out on residents in the Gaza Strip, screening for polymorphisms in 
NOS3, ACE and PAI-1 genes failed to show any significant association (Al Sallout, 2010).  
 
1.4 Breast Cancer 
  
Abnormal cell growth that forms in the tissues of the breast, usually the ducts and 
lobules is defined as Breast Cancer.  It can occur in both males and females, although male 
breast cancer is rare (American Medical Association, 2004). “Worldwide, it is estimated that 
more than one million women are diagnosed with breast cancer every year, and more than 
410,000 will die from the disease (Coughlin and Ekwueme, 2009).”  Life style, environmental 
factors and genetics all work together to predict the probability of developing breast cancer 
(Hartge, 2003). 
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Mutations in the BRCA1 and BRCA2 cancer predisposition genes are the principal 
cause of hereditary breast-ovarian cancer, however these mutations account for a small 
percentage of all breast cancer cases (Hall et al., 2009). 
Early detection is the best way to improve breast cancer prognosis and attempting to 
identify new genetic polymorphisms that may increase the susceptibility of developing the 
disease is a valuable contribution to the field of oncology.  
 
1.5 Hypothesis and Objectives  
 
 VKORC1 haplotypes are indicative of warfarin resistance and thrombophilia related 
events, by effecting mRNA expression levels and hence the activity of VKOR. Variation in the 
expression levels of this gene maybe associated with the pathophyiology of other diseases 
such as breast cancer and unexplained RPL. 
 
We hypothesize that the C allele of the VKORC1 +2255T/C SNP will be more prevalent 
among subjects with RPL, whereas the T allele will have a higher frequency within the breast 
cancer group. Furthermore, we predict a protective role for the AA haplotype of the GAS6 
SNP c.834+7 G >A, against breast cancer and RPL.  
 
The objectives of this study are; 
1) To test for potential new breast cancer and RPL biomarkers. 
2) To explore the relationship between variation in VK cycle activity, with the 
occurrence of breast cancer and RPL.  
3) To investigate a possible protective role for the GAS6 SNP c.834+7 G >A and the 
development of Breast Cancer and RPL. 
4) To contribute to the moving medical trend of individualized medicine. 
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Chapter II 
 
Experimental Approach 
 
Polymorphisms in the VKORC1 and GAS6 genes are potentially attractive Genetic 
Markers for Recurrent Pregnancy Loss and Breast Cancer. Case-control type studies were 
designed to investigate for possible associations. This project was conducted according to 
the standards of the Helsinki declaration, and approved by the research committee at Al-
Quds University. Experimental work was conducted at the Medical Research Centre on Abu-
Dies campus.  
The testing of our hypotheses required the use of three very common and well established 
molecular biology techniques; Polymerase Chain Reaction (PCR), Gel Electrophoresis, and 
Restriction Fragment Length Polymorphism (RFLP).  
The same SNPs are screened in both Breast Cancer and RPL cases, but are considered for 
different prospects; therefore each was approached as a separate study.      Participants 
were carefully genotyped at the loci in question, by amplifying the specified DNA fragments 
(PCR), then digested with restriction enzymes (RFLP), and documented by gel 
electrophoresis. Followed by a statistical analysis to test the extent with which a correlation 
can be established or denied. This chapter focuses on the techniques and procedure used for 
the experimental work.  
 
2.1 Participant selection 
2.1. 1 RPL - Control study 
The DNA samples of participants in this investigation were available in the lab from a 
previous study on RPL and Factor V Leiden mutation among the Palestinian population, with 
full medical history of RPL patients and their age-matched controls.  The inclusion criteria for 
the case group are women who endured three or more pregnancy losses in the first 
trimester or two more in the second trimester, without a known explanation. These women 
were otherwise healthy and had no anatomical abnormalities in the uterus. The control 
group was composed of age-matched women who had two or more successful pregnancies 
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and no medical problem. The number of participants that met the control criteria was 77, 
whereas 45 women classified as suitable RPL cases, all of whom had first trimester losses 
with the exception of one subject. The 122 subjects were from four major West Bank Cities; 
Bethlehem, Jericho, Ramallah, and Nablus.  
2.1.2 Breast Cancer – Control study  
81 breast cancer patients were included in this investigation, they were provided to 
us from a study that focused on risk assessment of breast cancer among Palestinians in the 
West Bank. The control group consisted of 84 post menopausal women with normal bone 
mass density and no history of clinical problems. They were personally called to verify the 
absence of breast cancer in their medical records and were considerably healthy women.   
 
2.2 DNA Extraction  
Isolation of Genomic DNA from fresh blood samples was previously done using commercially 
available Masterpure kits.  DNA was qualified, quantified and stored at -30
o
C until use.    
 
2.3 Polymerase Chain Reaction (PCR) 
   Development of the PCR technique in 1984 by Kary Mullis placed a milestone in the 
progress of Molecular Biology. This technique enabled scientists to amplify large quantities 
of selected segments of DNA in a short period of time.  The principle behind this technique is 
based on mimicking the natural process of DNA amplification; by providing all the necessary 
constituents such as dNTPs, divalent cations (Mg
+2
), buffer solution, and most importantly a 
heat stable DNA polymerase to synthesize new strands of DNA complementary to the 
designated template. To amplify the template strand, within the correct region two sets of 
primers (forward and reverse) are used, each annealing to the opposite end. A thermal 
cycler is utilized to provide the changes in temperature necessary for each step of the 
reaction to proceed. The first step of the reaction is separation of the double stranded DNA 
helix, denaturation of this structure requires a high temperature around (94- 96
o
C). The 
denaturation step described above is followed by the annealing step, in which the primers 
anneal to their complementary sequence on the template strand; the temperature at which 
this occurs varies with the sequences involved, usually between (50 – 65
o
C). After primer 
annealing, the temperature is raised to 72
o
C this marks the beginning of the elongation step, 
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new strand synthesis. At this temperature the enzyme Taq polymerase is at its optimal 
activity. The use of this heat stable polymerase, isolated from the thermophilic bacteria 
Thermus aquaticus, is the key behind the success of this technique (Nelson and Cox, 2005). 
 
2.3.1 PCR amplification for VKORC1 +2255 T/C  
 
The required 198- bp sequence containing SNP +2255 T/C was amplified by using the 
following primers (Invitrogen); 
 
Forward Primer (P1)  
 
 
‘
5_-TCTGAACCATGTGTCAGCCAGGACC-_3
’
 
 
Reverse Primer (P2) 
 
 
‘
5_-GAACAGAGAGAGGAACCAAGGGAGTGGA-_3
’
  
 
PCR-Ready 
TM 
High Yield tubes Cat. # PCR-Y-192, (Syntezza) were used for the amplification 
reactions. These tubes contain a ready mixture of dNTPs, heat stable DNA polymerase, 
divalent cations, PCR buffer and DNA loading dye.  
 
The following reaction mix was added to each tube; 
22 μL of distilled water, (Birzeit Pharmaceutical Company) 
1 μL P1 (1.5μg/μL) 
1 μL P2 (1.5μg/μL)  
1 μL (0.2μg/μL) Genomic DNA  
Total volume = 25μL 
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PCR reactions were preformed in GeneAMP
® 
PCR System 9700 PE (Applied Biosystems). DNA 
was denatured at 95 
o
C for 5 min followed by 35 cycles of 95
o
C for 45 sec (denaturation), 
58
o
C for 45 sec (annealing) and 72
o
C for 40 sec (elongation), and a concluding 7 min at 72
o
C 
for final extension. 
 
To confirm the presence of PCR products, samples were run for 50 min on 2% Agarose Gel 
Electrophoresis at 120V. (Refer to section 2.5 for more details.) 
 
2.3.2 PCR Amplification for GAS6 SNP 843+7 G>A 
 
The required 481- bp sequence containing SNP 843+7 G>A was amplified by using 
the following primers (Invitrogen); 
 
Forward Primer (P1)  
 
 
‘
5_- : TTCCCTCAACAAAGAGCCCG-_3
’
  
 
Reverse Primer (P2) 
 
  
‘
5_- TCTCATCCCAAACCTCCACA-_3
’
  
 
PCR-Ready 
TM 
High Yield tubes Cat. # PCR-Y-192, (Syntezza) were used for amplification 
reactions. These tubes contain a ready mixture of dNTPs, heat stable DNA polymerase, 
divalent cations, PCR buffer and DNA loading dye.  
 
The following reaction mix was added to each tube; 
22 μL of distilled water, (Birzeit Pharmaceutical Company) 
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1 μL P1 (1.5μg/μL) 
1 μL P2 (1.5μg/μL)  
1 μL (0.2μg/μL) Genomic DNA  
Total volume = 25μL 
 
PCR reactions were preformed in GeneAMP
® 
PCR System 9700 PE (Applied Biosystems). DNA 
was denatured at 95 
o
C for 5 min followed by 35 cycles of 95
o
C for 45 sec (denaturation), 
57
o
C for 45 sec (annealing) and 72
o
C for 60 sec (elongation), and a concluding 10 min at 72
o
C 
for final extension. 
 
To confirm the presence of PCR products, samples were run for 50 min on 2% Agarose Gel 
Electrophoresis at 120V. (Refer to section 2.5 for more details.) 
 
2.4 Restriction Fragment Length Polymorphisms (RFLP) 
RFLP is a common laboratory technique for the genotyping of SNPs. This method 
utilizes restriction enzymes to discriminate between two sequences, based on cleavage site 
recognition for only one of the alleles. Digestion of the DNA sequence will result in 
fragments of varying lengths that can be separated by gel electrophoresis, to verify the 
genotype (Saiki et al., 1985). 
 
2.4.1 Genotyping VKORC1 +2255 T/C polymorphism 
  PCR products were digested with the restriction enzyme NcoI (Invitrogen), which 
yields 2 DNA fragments of 26 and172 bp for the T allele, whereas the C allele is not cleaved 
and a single band of 198 bp appears on the gel (Wang et al., 2006). 
 
 The following digestion mix was added to10 μL of PCR product for each sample; 
* 1.5 μL of 10x buffer (Invitrogen), for a final concentration of 1x 
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* 0.5U NcoI (10U/ 1 μL) ≈ 0.05 μL  
* 3.45μL distilled water (Birzeit Pharmaceutical Company) 
Total volume = 15 μL 
 
Samples were incubated in a water bath at 37
o
C overnight, DNA fragments were then 
separated using 4% gel electrophoresis at 120 V for 75 min.  
 
2.4.2 Genotyping GAS6 843+7 G>A polymorphism 
PCR products were digested with the restriction enzyme AlwN I (Invitrogen), which 
yields 2 DNA fragments of 342 and 139 for the A allele, whereas the G allele is not cleaved 
and a single band of 481 bp appears on the gel (Muñoz, et al., 2004). 
 
 The following digestion mix was added to10 μL of PCR product for each sample; 
* 1.5 μL of 10x buffer (Invitrogen), for a final concentration of 1x 
* 0.5U AlwN I (10U/ 1 μL) ≈ 0.05 μL  
* 3.45μL distilled water (Birzeit Pharmaceutical Company) 
Total volume = 15 μL 
Samples were incubated overnight in a water bath at 37
o
C, DNA fragments were then 
separated using 3% gel electrophoresis for 75 min. at 120V.  
2.5 Gel electrophoresis 
Gel electrophoresis was used for two main reasons, firstly to confirm the presence 
of PCR products and secondly to separate digested DNA fragments.   
2%, 3% and 4% gels were prepared by mixing 2, 3 or 4 g of agarose powder with 100 ml of 
Tris-acetate-EDTA (TAE) buffer. This mixture was then stirred and heated over a hot plate 
until completely dissolved. 10 µL of Ethidium Bromide were added to the liquid gel before 
pouring in the casting tray. After solidification samples were loaded in the wells, 8 µL for PCR 
product and 12µL for digested samples. To measure the length of DNA bands on the gel, 2µL 
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of 100 bp DNA ladder (135 ng / µL) (BIONEER) were loaded with each run. After 50-75 min. 
of electrophoresis at 120 V, the gel was viewed under UV-light and photographed. 
 
2.6 Statistical analysis 
 Chi-square test was used to check the genotype distributions for Hardy-Weinberg 
equilibrium and to compare the observed allele and genotype frequencies in the patients 
with the controls.  Significances level was established at P < 0.05. 
SPSS Version 18 was also used to calculate odds ratio and 95% confidence interval.  
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Chapter III 
Results 
 
3.1 General Characteristics  
 
Haplotypes for VKORC1 and GAS6 were determined for participants in two case-
control type studies. One of the investigations undertaken, aimed towards studying the 
potential correlation between haplotype frequency and the incidence of Recurrent 
Pregnancy Loss in women that had three or more abortions of unknown etiology. The 
control group consisted of age matched healthy women with two or more successful 
pregnancies. The second study was conducted on Breast Cancer patients that had an 
aggressive prognosis and appeared at a relatively young age. The haplotype distribution for 
this group was compared to a cancer free control group of slightly older women. A summary 
of the number of participants in each group and their ages are described in Table 3.1.  
 
Table 3.1 Participant Distribution  
Groups Total 
Recurrent Pregnancy Loss 
 
Cases  Control  
 
# of women 45 77 
Mean age 30.5 ± 7.1 32.2 ± 4.3 
122 
Breast Cancer 
# of women 81 84 
Mean age 48.5 ± 9.6 56 ± 6.6 
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3.2 Genotyping of VKORC1 SNP +2255 T/C 
The polymorphism +2255 T/C was analyzed by amplifying a 198bp DNA fragment 
and confirmed by running on 2% gel agarose, stained with ethidium bromide and visualized 
under UV light as seen in Fig 3.1. This product was then digested with the restriction enzyme 
NocI and the digested products separated on 4% agarose gel as seen in Fig 3.2.   
 
           1    2     3     4     5    6     7     8    9   10    11  12   13   14   15   16    17  18  19  20   
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Fig 3.1 Representative Agarose gel for VKORC1 PCR product; the amplified 198 bp product 
is confirmed in lanes 2-19. The location of this segment is parallel to the 200bp band in the 
DNA ladder shown in lane 1.  
Lane 20 displays the results of a negative control for the PCR reaction (exclusion of DNA 
template) which validate the absences of DNA contamination.   
* 100 bp DNA marker ladder was employed in lane 1.  
 
             1    2    3     4    5    6    7    8    9   10  11  12  13  14  15  16  17  18  19  20   
 
Fig 3.2 Representative Agarose Gel for VKORC1 PCR product after digestion with the NocI 
restriction enzyme; NocI exclusively digests DNA fragments with the T allele resulting in 172 
and 26 bp fragments whereas the length of the DNA fragments with the C allele remain 
unchanged. Samples in lanes 2, 3, 5, 7-10, 16, & 18 display two bands at 198 and 172bp, 
therefore indicate a heterozygous haplotype of (CT). Complete digestion of the PCR product 
can be observed in lanes 4, 11, 12, 14, & 15 indicating homozygous (TT) haplotype. The 
198 bp 
198 
172  
 
 
 
 
20 
 
absence of digestion in lanes 6, 13, 17 & 19 is characteristic of the (CC) homozygous 
haplotype. Lane 20 contains a negative control sample, and lane 1 contains the 100bp DNA 
ladder. 
* The remaining 26bp fragment after digestion with NocI for T alleles can not be seen due to small 
size. 
                 
3.3 Genotyping of GAS6 SNP 843+7 G>A 
The GAS6 843+7 G>A polymorphism was analyzed by amplifying a 481bp DNA 
fragment. The PCR product was then run on 2% agarose gel and visualized under UV light as 
shown in Fig 3.3. This product was then digested with the restriction enzyme AlwN I and the 
digested products were analyzed by running on 3% gel as seen in Fig 3.4.   
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Fig 3.3 Representative Agarose Gel for GAS6 PCR product; the specified 481 bp product is 
confirmed in lanes 2-39. Lane 40 is a negative control that confirms the absences of DNA 
contamination. Lane 1 contains a 100bp DNA ladder marker. 
                 1      2    3    4    5    6     7     8    9  10   11  12  13  14   15  16   17   18   19   20   
  
Fig 3.4 Representative Agarose Gel for GAS6 PCR product after digestion with the AlwN I 
restriction enzyme; AlwN I exclusively digests DNA fragments with the A allele resulting in 
342 and 139bp DNA fragments, whereas the G allele is undigested. Samples in lanes 4, 7, 11, 
17, 19, 21, 22, 29, 30, 32, 34, 36, 37 & 38 display three DNA fragments at 481, 342, and 
139bp indicating partial digestion; these individuals have a heterozygous haplotype of (GA). 
Complete digestion of the 481 bp fragment can be observed in lanes 3 & 39 indicating a 
homozygous (AA) haplotype. The absence of digestion in lanes 5, 6, 8-10, 12-16, 23-28, 31, 
33, & 35 is characteristic of the (GG) homozygous haplotype. Lane 40 contains a negative 
control and lane 1 contains the 100bp DNA ladder marker. 
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3.4 Hardy-Weinberg equilibrium 
It is useful to determine if the alleles being studied in these subjects are in Hardy- 
Weinberg equilibrium, in order to rule out changes in the allele frequency from one 
generation to the next as a result of natural selection, mutation, migration or genetic drift 
(Klug, Cummings and Spencer 2005).  The chi-square test was used to check for fulfillment of 
the Hardy-Weinberg equilibrium in participants that were used as controls in the RPL (n=77) 
and Breast Cancer (n= 84) investigations. In addition, all individuals that did not meet the 
criteria for patient or control groups were also included (n=65). 
Table 3.2 Hardy-Weinberg equilibrium for the VKORC1 +2255 C/T allele 
 C allele frequency T allele frequency Total 
       0.562 (p)          +       0.438 (q)                 =  1 
 Expected Genotype frequencies  
  P2 + 2pq + q2                                                  =  1 
 CC CT TT 
 71.380 111.263 43.357 
 
  226   
 Observed  Genotype frequencies  
77 100 49 
 
   226 
  Chi-square test ( df = 1)  
X2= 2.308 
P > 0.05   No significant difference. 
Expectations of Hardy- Weinberg are fulfilled.  
*P > 0.05 for X
2
 less than 3.84 (df = 1)   
 
Table 3.3 Hardy-Weinberg equilibrium for the GAS6 SNP c.843+7 G>A 
 G allele frequency A allele frequency Total 
       0.6754 (p)          +       0.3246 (q)           =  1 
 Expected Genotype frequencies  
  P2 + 2pq + q2                                                =  1 
 GG GA AA 
 87.13 83.75 20.12 
 
  191   
 Observed  Genotype frequencies  
84 90 17 
 
   191 
  Chi-square test ( df = 1)  
X2= 1.063 
P > 0.05   No significant difference. 
Expectations of Hardy- Weinberg are fulfilled.  
* P > 0.05 for X
2
 less than 3.84 (df = 1)   
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Patient groups fulfilled expectations for the Hardy-Weinberg equilibrium for both VKORC1 
and GAS6. (Calculations not shown) 
 
3.4.1 VKORC1 +2255 T/C Haplotype frequencies in RPL patients and Controls 
 
  The haplotype distribution for the +2255T/C polymorphism among patients (n= 45) 
and controls (n= 77) is summarized in Fig 3.5. The CC, CT, and TT haplotype frequencies in 
patients with RPL were 15.6% (n= 7), 55.6% (n=25), and 28.9% (n=13), while the frequency in 
the control group was 29.9% (n= 23), 44.2% (n= 34) and 26% (n= 20), respectively. Chi-
square test (df= 2) was used to determine if the differences in the two groups is 
considerable. The P value was found to be 0.20, which indicates no significant difference in 
haplotype distribution. 
 
Fig. 3.5 VKORC1 +2255 T/ C Haplotype distribution in RPL patients and Controls (P = 0.20) 
 
To evaluate the association of the C allele with the occurrence of RPL, CC and CT 
haplotypes were joined in one group, the C allele exerts a dominant effect (Wang et al., 
2006), and the Odds ratio (OR) and 95% Confidence Interval (CI) were calculated. As shown 
in table 3.4  
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Table 3.4 Risk assessment of VKORC1 SNP + 2255 with RPL  
                   Haplotypes ( % ) 
 CC + CT TT 
Controls  74 (n = 57) 26 ( n= 20) 
RPL Cases 71.1(n= 32) 28.9 (n= 13) 
X2 test (df= 1) ;  P =   0.73   
OR ( 95% CI)    =  1.16 ( 0.51 - 2.63) 
The results indicate no statistically significant association between the VKORC1 haplotypes 
examined and RPL occurrence; although a slight difference is noticeable between the 
groups.  
3.4.2 GAS6 c.843+7 G>A Haplotype frequencies in RPL patients and Controls 
 
The haplotype distribution for the GAS6 c.843+7 G>A polymorphism among RPL patients (n= 
45) and controls (n= 77) is summarized in Fig 3.6. The GG, GA, and AA frequencies in RPL 
patients were 42% (n= 19), 51% (n= 23), and 6.7% (n= 3), respectively, and in the controls 
were 37.7% (n= 29), 53.2% (n= 41), and 9.1% (n= 7). The P value 0.83 indicates an 
insignificant difference between the two groups.  
 
Fig. 3.6 GAS6 c.843+7 G>A Haplotype distribution in RPL patients and Controls (P= 0.83) 
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To determine if the AA haplotype is associated with a decreased risk of RPL, the GG 
and GA haplotypes were placed in one group and compared to the AA haplotype. OR and 
95% CI were calculated (table 3.5) It is not clearly established if either allele exerts a 
dominant effect, therefore allele frequencies in the examined groups were taken into 
consideration, OR and 95% CI were computed as well, as shown in table 3.5.    
 
Table 3.5 Risk assessment of GAS6 SNP c.843+7 G>A with RPL  
Haplotype Frequency (%)   Allele Frequency (%)  
GG +GA AA G A 
Controls 90.9% (n= 70) 9.1% (n= 7) 63.6% (n= 98) 36.4% (n= 56) 
RPL Cases 93.3% (n= 42) 6.7% (n= 3) 67.8% ( n= 61) 32.2% (n= 29) 
X2 Test Df= 2;  P= 0.64 df= 1; P= 0.51 
OR ( 95% CI) 0.71 (0.18 – 2.91)  0.83 ( 0.48 – 1.44) 
 
These results show no significant association between the GAS6 haplotypes and RPL 
occurrence.  
3.5.1 VKORC1 +2255 T/C Haplotype frequencies in Breast Cancer patients and Controls 
 
  The haplotype distribution for the +2255T/C polymorphism among breast cancer 
patients (n= 81) and controls (n= 84) is summarized in Fig 3.7. The CC, CT, and TT haplotype 
frequencies in breast cancer patients were 22.2% (n= 18), 45.7% (n= 37), and 32.1% (n= 26) 
and among controls were 38.1% (n= 32), 45.2% (n= 38) and 16.7% (n= 14), respectively.  Chi-
square test (df= 2) was used to determine if the differences in allele distribution between 
the two groups is considerable. P value was found to be 0.02, which indicates a significant 
difference. 
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Fig. 3.7 VKORC1 +2255 T/ C Haplotype distribution in Breast Cancer patients and Controls 
(P = 0.02) 
To evaluate the association of the C allele with the occurrence of Breast cancer, the 
CC and CT haplotypes were joined as one category and the TT haplotype in a separate 
category. OR and 95% CI, were calculated as shown in table 3.6. 
 
Table 3.6 Risk assessment of VKORC1 SNP + 2255 with breast cancer  
                   Haplotypes ( % ) 
 CC + CT TT 
Controls  83.3 (n = 70) 16.7 ( n= 14) 
BC Cases 67.9 (n = 55) 32.1 (n=  26) 
X2 test (df= 1) ;  P =   0.02   
OR ( 95% CI)    =  2.36 ( 1.13 - 4.95) 
 
The results clearly indicate that the TT haplotype is significantly associated with breast 
cancer occurrence.  
3.5.2 GAS6 c.843+7 G>A Haplotype frequencies in Breast Cancer patients and Controls 
 
The haplotype distribution for the GAS6 c.843+7 G>A polymorphism among breast cancer 
patients (n= 81) and controls (n= 84) is summarized in Fig 3.8. The GG, GA, and AA 
frequencies in patients were 38.3% (n= 31), 54.3% (n= 44), and 7.4 (n= 6) and the controls 
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were 46.4% (n= 39), 42.9% (n= 36), and 10.7% (n= 9), respectively. The P value 0.32 indicates 
an insignificant difference between the two groups.  
      Fig. 
3.8 GAS6 c.843+7 G>A Haplotype distribution in BC patients and Controls (P= 0.32) 
 
To determine if the AA haplotype is associated with a decreased risk of breast cancer, the 
GG and GA haplotypes were placed in one group and the AA haplotypes in a separate group. 
OR and 95% CI were calculated, as shown in table 3.7.     
 
Table 3.7 Risk assessment of GAS6 SNP c.843+7 G>A with Breast Cancer  
Haplotype Frequency (%)   Allele Frequency (%)  
GG +GA AA G A 
Controls 89.3 (n= 75) 10.7 (n=9) 68.5 (n= 115) 31.5 (n= 53) 
BC Cases 92.6 (n= 75) 7.4 (n= 6) 65.4 ( n= 106) 34.6 (n= 56) 
X2 Test df= 2;  P= 0.46 df= 1; P= 0.56 
OR ( 95% CI) 0.67 (0.23 – 1.96) 1.15 ( 0.72 – 1.81) 
 
These results indicate no significant association between the GAS6 Haplotypes and Breast 
cancer occurrence. 
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Chapter IV 
Discussion 
 
Breast Cancer and RPL are serious health concerns to an increasing portion of 
Palestinian women. Providing a better understanding of these complex diseases facilitates 
the medical trend towards a more individualized patient approach. In recent years, research 
efforts to understand genetic susceptibility to diseases and predicting treatment response 
based on genotype have been on the rise. Numerous studies have focused on investigating 
correlations between SNPs in specific target genes and the incidence of disease among 
various populations, which proves to be a valid risk assessment approach.  
 
The present study is the first of its kind to investigate a correlation between VKORC1 
SNP +2255 T/C and GAS6 SNP 843+7 G>A with the occurrence of RPL and Breast Cancer. 
Throughout the course of this research, each disease was approached as a separate study 
although the methodology was identical. In each case the haplotype frequency was 
compared between patients and control subjects to examine whether a correlation can be 
established.  
 
RPL is a heterogeneous disease and the etiology of half the cases remains 
unexplained ( Kwak-Kim, 2009),  Thrombophilia may be a contributing factor in 40-60% of 
unexplained RPL cases ( Brenner et al., 1997). Thrombophilia risk factors are either acquired 
or inherited. Acquired factors include smoking, obesity, oral contraceptive pills, 
immobilization, and pregnancy (Cooper, 1994). Inherited factors include deficiencies in 
protein S or protein C, mutations in some of the proteolytic cascade proteins involved in 
hemostasis such as Factor II and Factor V, and Methylenetetrahydrofolate reductase 
(Cooper, 1994). A clear association has been established between fetal loss and certain 
thrombophilic states such as antiphospholipid syndromes, and antithrombin deficiency or a 
combination of these defects, although reports on the prevalence of inherited 
prothrombotic defects such as Factor V Leiden mutation and Methylenetetrahydrofolate 
reductase C677T polymorphism in fetal loss are contradictory ( Biswas et al., 2008).   
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 Unexplained RPL among Palestinian women has attracted research efforts of several 
local groups. Two parallel studies were conducted on the association of Factor V Leiden with 
RPL among patients form the northern and southern area of the West Bank. The results from 
both studies were jointly analyzed and a significant association was observed (Hussein et al., 
2010).  
 
 One of the main objectives of the current project is to test whether newly identified 
polymorphisms linked to thrombophilia could account for unexplained cases of RPL. 
Recently recognized polymorphisms in VKORC1 +2255 T/C and GAS6 843+7 G>A have been 
linked to increased incidence of vascular disease and stroke, respectively (Wang et al., 2007 
and Muñoz et al., 2004). 
 
Variants in VKORC1 could serve as a common genetic risk factor for all vascular 
diseases. It’s involved in γ-carboxylation of hemostatic and nonhemostatic proteins by 
controlling the vitamin K cycle. Polymorphisms of VKORC1 have been shown to affect the 
expression and activity of VKOR and thus blood clotting (Yuan et al., 2005 and Rieder et al., 
2005). The presence of the C allele
 
at the +2255 locus conferred an almost 2-fold increase in 
vascular
 
disease risk within the Chinese population (Wang et al., 2006). This C
 
allele reflects 
the G-C-G-C-A
 
haplotype of the VKORC1 gene (Wang et al., 2006) and mRNA levels in the 
group with the G-C-G-C-A haplotype are approximately 3 times higher then the wild-type 
group (Rieder
 
et al, 2005).  
 
In our investigation, 45 women with unexplained RPL and 77 age- matched controls 
were genotyped at the VKORC1 (+2255 T/C) locus. No significant difference was observed in 
haplotype distribution among the two groups (P = 0.20).   
The lack of association observed could be due to; first, the possibility that RPL among the 
participants is not thrombophilia related. Second, since no prior studies regarding VKORC1 
polymorphisms or its haplotype block have been conducted in the Palestinian population it 
is difficult to assume compliance with other populations, regarding the link of this 
polymorphism with thrombophilia. Third, perhaps the number of participants in the study is 
not adequate to show a significant difference.  
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 Some populations have shown no association between this polymorphism and vascular 
disease. A German case- control study on stroke patients found no link between VKORC1 
SNPs and increased risk for stroke (Arnold  et al., 2008).  In addition, a USA study found no 
relationship with VKORC1 variants and arterial or venous thrombosis (Hindorff  et al., 2007). 
One may speculate that the results observed in our study may be due to the lack of 
association of this SNP with thrombophilia in the Palestinian population. Therefore 
thrombophilia can not be dismissed as a cause in the unexplained RPL cases.  
 
GAS6 represents another candidate gene with linkage to thrombophilia. The A allele 
in the GAS6 c.834+7G>A polymorphism was shown to be associated with lower risk for 
stroke incidence (Muñoz et al., 2007).  Studies focusing on the role of Gas6 in coagulation 
pathways have shown that Gas6  is a platelet response amplifier that plays an important role 
in pathological thrombosis, and that Gas6-neutralising antibodies inhibit platelet aggregation 
in vitro (Angelillo-Scherrer et al., 2001). Furthermore, when the Gas6 receptor is blocked, 
initial platelet aggregation does occur, but stabilisation of platelet aggregates is impaired 
and mice are protected against life-threatening thrombosis (Angelillo-Scherrer et al., 2005). 
Recent publications have confirmed that all three RTKs (Axl, Tyro3 and Mer) are present on 
human platelets and that GAS6 expression is high in blood (Gould et al, 2005 and Balogh et 
al, 2005). More studies are required to verify the role of variants in this gene with expression 
levels; Up- or down-regulation of GAS6 expression from vascular cells appears to be 
important for its function (Muñoz  et al., 2007). 
 
  After screening of the GAS6 polymorphism in our study, no significant difference in 
the frequency of the protective AA haplotype was observed between the control compared 
to the case group (P = 0.83). This could be due to similar reasons as explained for the 
VKORC1 polymorphism.  
   
Breast Cancer is one of the most devastating illnesses affecting the health of women 
today. Early detection is the key to better prognosis and research efforts that aim to identify 
genetic markers associated with an increased risk of occurrence constitute a valuable 
contribution to the field. Vitamin K2 (VK2), menaquinones, can exert cell growth inhibitory 
effects in various human cancer cells and animal models (Li et al., 2010 and Nimptsch et al., 
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2010). Furthermore, the dietary consumption of VK2 is associated with a reduced risk of 
incident and fatal cancer (Nimptsch K et al., 2010). Considering the importance of VKORC1 in 
the regulation of the vitamin K cycle, variants in this gene are attractive candidates to study 
their potential association with cancer. A case- control study on 81 Breast Cancer patients 
showed a significant difference in haplotype distribution for the VKORC1 +2255T/C SNP 
compared to controls (P = 0.02). The TT haplotype was found in 32% of the Breast Cancer 
patients, compared to 16.7% of the control group. The CC and CT haplotypes were found in 
83.3% of controls and 67.9% of patients. Therefore, the T allele conferred a more than 2 fold 
increased risk for developing Breast Cancer OR 2.36, 95% CI (1.13 - 4.95).  
 
  VK2 induces apoptosis through one or more mitochondrial pathways (Green and 
Reed, 1998), and it is associated with the generation of superoxide, a reactive oxygen 
species (Shibayama-ImazuT et al, 2008). The production of superoxide and the induction of 
apoptosis by VK2 were almost completely inhibited by cycloheximide, a protein synthesis 
inhibitor, suggesting de novo synthesis of enzymes involved in the production of superoxide 
may be required for apoptosis (Shibayama-Imazu et al., 2006). One may speculate that VK2 
affects protein synthesis either by directly impacting gene regulation at the transcriptional 
level or through an unidentified intermediate factor that requires VK2 for post 
transcriptional modification. In either case, if VK2 involvement generates Vitamin K epoxide 
and the reduced form is required for continuation in activity, then the rate of reduction by 
VKOR will affect the progression of cells into apoptosis. The T allele of VKORC1 is linked with 
a slower vitamin k cycle, this may account for the higher prevalence of the T allele with 
Breast Cancer patients. Interestingly, in another study VKORC1 has been found to be over 
expressed in tumour tissues and may play a possible role in angiogenesis (Wang et al., 2005).  
Another possible explanation is that VKORC1 haplotypes are only markers for
 
Linkage disequilibrium and some genes in the linkage region independent of or in
 
conjunction with VKORC1 confer susceptibility to Breast Cancer. At least 6 other genes are 
found in the natural haplotype block
 
over the 68 000 bases around VKORC1 (International 
HapMap Consortium, 2003); ZNF668 (zinc finger protein),
 
ZNF646, BCKDK (branched chain 
ketoacid dehydrogenase kinase),
 
MYST1 (histone acetyltransferase1), PRSS8 (protease serine 
8),
 
and PRSS36. However, the function of these genes is still not clear (Wang et al., 2006). 
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  Gas6 exerts mitogenic activity in cell lines, and has been shown to commence 
coordinated entry into the S phase of the cell cycle, when bound to endogenous Axl 
(Goruppi et al., 1996). Over expression of receptors for Gas6 belonging to the Axl/Tyro3 
family had been reported in human mammary tumours, leukaemia and lung cancers (Mc 
Cormack et al., 2008).  Gas6 is up-regulated more than 23-folds by progesterone acting 
through the progesterone receptor B in breast cancer cell lines (Richer et al, 2002). 
Furthermore, the GAS6 locus has recently been described as a target for amplification in 
mouse models and in human breast cancer (Abba et al., 2007).  Therefore, polymorphisms in 
the GAS6 gene which may be associated with expression levels could be interesting potential 
biomarker for breast cancer incidence. Currently there are no studies that connect the GAS6 
c.834+7G>A polymorphism with changes in gene expression at this locus. Although, the A 
allele was linked with a decreased incidence of stroke (Muñoz  et al., 2007). This encouraged 
us to explore the possible relationship of a protective role for the A allele in breast cancer, 
based on the reasoning that Gas6 is involved in clot stability, and the A allele is linked with a 
decrease in clot stability presumably by lower GAS6 expression levels. Then, perhaps the A 
allele could be protective in Breast Cancer as well by decreasing mitogenic activity of Gas6.  
However, our data indicates that no significance in haplotype distribution was observed 
between breast cancer patients compared to controls (P = 0.32).  
   
In conclusion, a significant prevalence of the T allele of the VKORC1 haplotype was 
established among breast cancer patients (P = 0.02) where as, the A allele of GAS6 SNP 
showed no protective advantage (P = 0.32). In addition, no significant difference in 
haplotype distribution was observed for either GAS6 c.834+7G>A (P=0.83) or VKORC1 +2255 
T/C (P = 0.20) among RPL cases compared to the control group. 
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Chapter V 
Recommendations 
 
RPL is a multi-factorial disease, it is highly unlikely that a single locus can predict 
pregnancy outcome alone. Multi-analysis of the association between numerous haplotypes 
involved with thrombophilia is recommended in these patients.  
 
Further research to study the association of VKORC1 variants with warfarin resistance in the 
Palestinian population, would be invaluable. One of the many potential medical treatments 
to benefit from modifying anti-coagulant dose would be RPL patients with thrombophilia 
etiology. 
 
In addition, a clear elaboration of the GAS6 c.834+7G>A polymorphism involvement in gene 
expression is needed.  Also a search for other GAS6 polymorphisms or mutations that can 
modify gene expression would benefit research efforts in RPL and Breast Cancer alike. 
 
The association of the VKORC1 T allele with Breast Cancer is a promising first step, although 
many other factors influence the VK status in the body such as, diet, absorption rate and 
transport (Booth and Al Rajabi, 2008). These factors should be taken into further account.     
 
A recommended future project should focus on further elucidating the involvement of VK in 
apoptosis, perhaps searching for an unidentified VK- dependent factor in the signalling 
cascade or a direct role of VK in regulating gene expression.  
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